HOME >> BIOLOGY >> NEWS
New transgenic rat model of ALS expands research possibilities

A team of scientists led by drug maker Wyeth-Ayerst and Johns Hopkins have engineered and tested a new rat model of Lou Gehrig's disease they say is far easier to work with than earlier mouse models.

Because of their larger size, the rats should expedite evaluation of novel treatments, such as those using stem cells, as well as deepen understanding of the fatal disease also known as amyotrophic lateral sclerosis (ALS), the scientists say. The "transgenic" rat, which carries a human gene, already has revealed the important role played by brain cells called astrocytes, a role obscured in mice.

The ALS rat, believed to be the first transgenic rat model of a neurodegenerative disease, moves from onset of symptoms through to ALS-like disability more quickly than ALS mice, making changes in cells in the rats more striking from day to day, the scientists report in the Jan. 29 online edition of the Proceedings of the National Academy of Sciences.

"The transgenic rats are a powerful tool," says neurologist Jeffrey Rothstein, M.D., director of the Center for ALS Research at Johns Hopkins and an author of the report. "Mice are just too small, for example, for reliable infusions into their spinal cords, the direction research on stem cell treatment is heading."

Scientists at Wyeth-Ayerst engineered the rats to carry an abnormal human gene for superoxide dismutase (SOD1), an enzyme that normally breaks down free radicals, highly reactive molecules that quickly damage DNA and kill cells. Faulty SOD1 behavior, caused by a number of different genetic mutations, is at the root of roughly one-fifth of inherited ALS cases.

The SOD1 rats, like the SOD1 mice before them, develop a disease very similar to ALS in humans, which is characterized by the death of motor nerve cells throughout the central nervous system. The rats are "symptom-free" for a longer time, but then deteriorate much more rapidly than the mice.

While the faster disease
'"/>

Contact: Joanna Downer
jdowner1@jhmi.edu
410-614-5105
Johns Hopkins Medical Institutions
28-Jan-2002


Page: 1 2 3

Related biology news :

1. Inhibition of cathepsin proteases inhibits tumor formation in transgenic mice
2. UGA researchers use transgenic trees to help clean up toxic waste site
3. Could Bt transgenic crops have nutritionally favourable effects on insects?
4. Scientists transgenic chicken aids embryo research
5. Scientists report first transgenic animal developed via retroviral DNA insertion into male germ-line stem cells
6. Eating transgenic sausages
7. Dairy scientist advances field of transgenics and knowledge of growth hormones
8. Scientists develop most efficient mouse cloning strategy to date, create transgenic clone
9. New transgenic mouse likely to advance Alzheimers disease research
10. University of Florida researchers test drug from transgenic sheep in study at Shands at UF teaching hospital
11. Jefferson scientists create first transgenic mouse model of hepatitis B-based liver disease

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: New transgenic rat model ALS expands research possibilities

(Date:12/11/2014)... 2014  Data Sciences International (DSI), the global ... new series of digital telemetry implants to meet ... series, part of the PhysioTel™ Digital platform, was ... physiologic data when incorporating functional endpoints into repeat-dose ... toxicology studies has evolved from short ECG strips ...
(Date:12/10/2014)... Dec. 9, 2014 CIE San Diego has ... provides the connective tissue that enhances care coordination among ... easily share client-level information; earned a second $1 million ... organizations serving seniors aging in community and; will be ... December 11 th 4-6p. CIE San ...
(Date:12/5/2014)... -- Tute Genomics, a leader in cloud-based solutions for genome ... led by UK-based Eurovestech. Peak Ventures and a number ... "We are at a pivotal time in ... seeks new approaches for the diagnosis, treatment and prevention ... and CEO of Tute Genomics. "One of the main ...
Breaking Biology News(10 mins):New telemetry implants expected to change how large animal toxicology studies are conducted 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
Cached News: